Yahoo Finance

Operations: The company generates revenue from its pharmaceutical product Feraccru®/Accrufer®, totaling $21.47 million.

Market Cap: £22.48M

Shield Therapeutics plc, with a market cap of £22.48 million, is navigating financial challenges typical of penny stocks. Despite generating US$21.47 million in revenue from its pharmaceutical product Feraccru®/Accrufer®, the company remains unprofitable and faces increasing losses over five years at 41.1% annually. The recent £8.69 million equity offering aims to bolster its cash runway beyond four months, though high net debt to equity (2140.5%) persists as a concern. While short-term assets exceed liabilities, share price volatility and an inexperienced management team add layers of risk for investors considering this stock's potential growth trajectory amidst industry competition.

• Take a closer look at Shield Therapeutics' potential here in our financial health report.

• Explore Shield Therapeutics' analyst forecasts in our growth report.

Tanfield Group

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Tanfield Group PLC is an investment company with a market cap of £6.13 million, holding a 49% interest in Snorkel International Holdings LLC, which manufactures various types of aerial lifts such as scissor lifts and boom lifts.

Operations: Tanfield Group does not report any specific revenue segments.

Market Cap: £6.13M

Tanfield Group PLC, with a market cap of £6.13 million, is pre-revenue and unprofitable but has reduced its losses over the past five years by 44.9% annually. The company holds a 49% interest in Snorkel International Holdings LLC and remains debt-free, which provides some financial stability. Its short-term assets (£3.4M) comfortably cover short-term liabilities (£50K), though there's insufficient data on cash runway or management experience to fully assess operational resilience. Recent earnings showed a narrowed net loss of £0.097 million for H1 2024, reflecting improved cost management despite ongoing profitability challenges typical of penny stocks.

• Jump into the full analysis health report here for a deeper understanding of Tanfield Group.

• Examine Tanfield Group's past performance report to understand how it has performed in prior years.

Taking Advantage

• Click here to access our complete index of 470 UK Penny Stocks.

• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.

• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Jump on the AI train with fast growing tech companies forging a new era of innovation.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AIM:NBB AIM:STX and AIM:TAN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com